Announcement of Availability for Entinostat
January 29, 2026
The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using entinostat, a class I histone deacetylase (HDAC) inhibitor, which is being developed by CTEP as an anticancer agent. CTEP will also consider requests to supply entinostat for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data.
Entinostat (SNDX-275 or MS-275) is an orally bioavailable, potent, and selective small molecule HDACinhibitor. Entinostat specifically inhibits the class I HDACs, HDAC1 and HDAC3, promoting hyperacetylation of histones and gene activation. This results in inhibition of cellular proliferation, terminal differentiation, and apoptosis of cancer cells (Connolly et al., 2017). Entinostat has been studied in combination with both hormone therapy and programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) antagonists in multiple solid tumors, leading to a disruption in estrogen signaling and re-sensitization to endocrine therapy, down-regulation of immune suppressive cell number and function, increased antigen presentation, and enhanced cytotoxic T-cell activity (Entinostat, Syndax Pharmaceuticals).Additionally, entinostat has been studied in both solid tumors and hematologic malignancies in combination with DNA methyltransferase (DNMT) inhibitor therapies (Connolly et al., 2017; Knipstein and Gore, 2011)
Further instructions for completing and submitting the forms may be found within the respective documents.Because CTEP will be supporting a limited number of studies, please submit all study proposals by 2 months from release date.
If you are a HCC Investigator interested in submitting an LOI using Entinostat through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).
Questions may be addressed to Dr. Lorraine Pelosof (lorraine.pelosof@nih.gov) Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).